Tofogliflozin hydrate etyltransferase Inhibitor II iNOS and COX-2 in A431

iNOS and COX-2 in A431 cells

(2005) Nature

23(16-42)39-40-24(43)9-4-3-5-12-41-25(44)10-11-26(41)45)14-19-29(22)36(50)31-30(34(19)48)33(47)18-7-6-8-21(52-2)28(18)35(31)49/h6-8

PP-121 induces a G0/G1 arrest in LN220

Sirajuddin P

Tofogliflozin hydrate etyltransferase Inhibitor II iNOS and COX-2 in A431Tofogliflozin, also known as CSG 452, is a potent and high selective SGLT2 inhibitor under development the treatment of diabetes mellitus. Tofogliflozin improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. Tofogliflozin dose dependently suppressed glucose entry into tubular cells. High glucose exposure (30 mM) for 4 and 24 h significantly increased oxidative stress generation in tubular cells, which were